Skip to main content

Table 2 Perioperative period

From: Impact on grafted kidney function of rocuronium-sugammadex vs cisatracurium-neostigmine strategy for neuromuscular block management. An Italian single-center, 2014-2017 retrospective cohort case-control study

Medications NEO (n = 175) SUG (n = 175) P value
Intraoperative period
 Intravenous anesthesia, n (%) 62 (35.4) 56 (32) 0.572
 Inhalational anesthesia, n (%)  
• Sevoflurane, n (%) 65 (37.1) 58 (33.1) 0.502
• Desflurane, n (%) 48 (27.4) 61 (34.9) 0.166
 Fentanyl, n (%) 67 (38.3) 72 (41.1) 0.662
 Remifentanil, n (%) 86 (49.1) 92 (52.6) 0.593
 Ketamine, n (%) 20 (11.4) 15 (8.6) 0.476
 Paracetamol, n (%) 153 (87.4) 159 (90.9) 0.391
 Morphine, n (%) 27 (15.4) 25 (14.3) 0.881
 Tramadol, n (%) 99 (56.6.4) 92(52.6.3) 0.520
 Vasoactive drugs, n (%) 38 (21.7) 35 (20) 0.793
 Droperidol, n (%) 39 (22.3.9) 42 (24) 0.800
 Ondansetron, n (%) 149 (85.1) 141 (80.6) 0.321
 Clonidine, n (%) 15 (8.6) 9 (5.1) 0.290
 Pethidine, n (%) 10 (5.7) 7 (4.0) 0.620
 Cisatracurium, mg [IQR] 36.9 [21.8-70.1] 0.0 [0.0-0.0] < 0.001
 Rocuronium, mg [IQR] 0.0 [0.0-0.0] 110.0 [60.0-220.0] < 0.001
 Atropine (%) 141 (80.6) 0.0 (0.0) < 0.001
 Neostigmine (%) 175.0 (100) 0.0 (0.0) < 0.001
 Neostigmine, μg/kg 29.9 [12.2-67.4] 0.0 [0.0-0.0] < 0.001
 Sugammadex 2 mg/kg (%) 0 (0.0) 101 (57.7) < 0.001
 Sugammadex 4 mg/kg (%) 0 (0.0) 74 (42.3) < 0.001
 Fluid total, ml 2100 [1800-2500] 2100 [1700-2400] 0.168
 Surgery, min [IQR] 185 [155-237.5] 180 [150-225] 0.116
 Anesthesia, min [IQR] 235 [210-292.5] 240 [205-285] 0.589
Postoperative period
 SpO2 at T15, % 99 [98-99] 99 [98-100] 0.117
 HR at T15, beats/min [IQR] 81.0 [71-91] 82 [72.5-92.5] 0.271
 SBP at T15, mmHg [IQR] 140.0 [130-154.5] 145 [128.5-157.5] 0.503
 DBP at T15, mmHg [IQR] 80.0 [71.0-87.5.5] 79 [70.0-88.0] 0.348
 pH at T15 [IQR] 7.36 [7.33-7.4] 7.36 [7.33-7.39] 0.671
 PaO2 at T15, mmHg [IQR] 88.6 [76-103.2] 89.2 [79.5-101.4] 0.253
 PaCO2 at T15, mmHg [IQR] 39.6 [36.2-42.4] 39.7 [36.4-43.6] 0.207
 Pain NRS>3 at T15, n (%) 18 (10.3) 14 (8.0) 0.579
 PONV NRS>3 at T15, n (%) 13 (7.4) 8 (4.6) 0.368
 Hypoxemia, n (%) 11 (6.3) 1 (0.6) 0.006
 Antihypertensive drugs, n (%) 16 (9.1) 9 (5.1) 0.212
 PACU stay, min [IQR] 90 [60-105] 70 [60.0-90.0] < 0.001
 ICU admission, n (%) 14 [8.0] 1 [0.6] 0.001
  1. NMB neuromuscular block, NEO group of patients receiving neostigmine for reversal of cisatracurium-induced NMB, SUG group of patients receiving sugammadex for reversal of rocuronium-induced NMB; vasoactive drugs: repeated administration of etilefrine or ephedrine, or dopamine infusion; surgery: time from skin incision to the placement of the last suture; anesthesia: time from tracheal intubation to tracheal extubation; PACU (post-anesthesia care unit): time from PACU admission to discharge to the surgical ward, ICU intensive care unit, SpO2 peripheral arterial blood oxygen saturation, PaO2 arterial partial pressure of oxygen, PaCO2 arterial partial pressure of carbon dioxide, HR heart rate, SBP systolic arterial blood pressure, DBP diastolic arterial blood pressure, T15 15 min after tracheal extubation, NRS numeric rating scale, PONV postoperative nausea and vomiting, hypoxemia oxygen desaturation (SaO2<90%) requiring treatment; antihypertensive drugs: clonidine, urapidil; amlodipine, labetalol; diltiazem. Data are expressed as median [interquartile range, IQR] or number, n (%)